Testing effectiveness (Phase 2)Study completedNCT01302847
What this trial is testing
Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 181